The company
Propanc Biopharma, Inc.
PPCB · Nasdaq
PPCB stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 80.6% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).
Statistics
- Rotation
- Not moving yet
- Weeks in an uptrend
- out for 52
- Industry in uptrend
- 16% -15 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $0
- Officials’ trades on record
- 0
- Institutions holding
- 4 (-1)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
No member of Congress or official has disclosed a trade in it.
Insiders
No open-market buy or sale by its insiders on record.
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| JANE STREET GROUP, LLCreduced · filed 14 Aug 2026 | 25,550$38K | -117,662−82.2% |
| CITADEL ADVISORS LLCnew · filed 14 Aug 2026 | 12,090$18K | +12,090 |
| Caitong International Asset Management Co., Ltdnew · filed 5 Aug 2026 | 2$3 | +2 |
| MERCER GLOBAL ADVISORS INCnew · filed 11 Aug 2026 | 1$2 | +1 |
News
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.